



Nadeem Aslam MBBS, FACE, FACP

* Nadeem Aslam provides medical services through Dr. Nadeem Aslam Medicine Professional Corporation

Etobicoke #2B- 1723 Kipling Avenue, Etobicoke, Ontario, M9R 4E1 Canada

Tel (416) 645-1035

CURRICULUM VITAE

Education, Certification & Licenses

2011	Recertified in American Board of Endocrinology	
2010	Recertified in American Board of Internal Medicine	
2001	American Board of Endocrinology	
2000	US Board Certified	American Board of Internal Medicine
1999-2011	Fellowship in Endocrinology and Metabolism	Veterans Affairs Medical Center, Phoenix, Arizona
1996-1999	Internship and Residency in Internal Medicine	Muhlenberg Hospital, Plainfield, New Jersey
1985-1991	M.B.B.S	Allama Iqbal Medical School, Lahore, Pakistan
1982-1984	H.Sc. in Pre-medical sciences	Pakistan Embassy School, Jeddah, Saudi Arabia

Professional Activities

2013	Associate, Endocrinologist	LMC Diabetes & Endocrinology
06/2012-02/2013	Private Practice	Central New York
02/2012-05/2012	Locum Tenens- Staff Care	Department of Endocrinology, VA Medical Center, Syracuse, New York
07/2010-01/2012	Medical Director of Endocrinology	Community Hospital, Lewiston, New York
04/2009-03/2010	Locum Tenens- Staff Care	Vista Health Endocrinology, Bullhead City, Arizona
08/2008-01/2009	Private Practice	Phoenix, Arizona
07/2002-07/2008	Associate Medical Director and Endocrinologist	Community Health Center- Arizona
07/1999-09/2001	Fellowship in Endocrinology, Diabetes & Metabolism	Veterans Affairs Medical Center, Phoenix, Arizona
07/1996-06/1999	Residency in Internal Medicine	Muhlenberg Hospital, New Jersey
04/1995-12/1995	Observership	The Scarborough Grace Hospital, Toronto, Canada The Mississauga Hospital, Toronto, Canada Veterans Affairs Medical Center, Phoenix, Arizona
03/1993-09/1994	Student	Kaplan Institute of Toronto
08/1992-02/1993	Externship	Khan Polyclinic, Lahore, Pakistan
01/1992-03/1992	Externship	Department of Dermatology at Sir Ganga Ram Hospital, Lahore, Pakistan

Achievements, Associations & Specialties

Association	Fellow, American Association of Clinical Endocrinologists (AACE)
	Member, The Endocrine Society
	Fellow, American College of Physicians (ACP)
	Member, Pakistan Medical and Dental Council (PMDC)
	Member, European Association for the study of Diabetes (EASD)

Clinical Trials & Research Activities

2013 - 2016	REWIND (Eli Lilly), R727CL1110 (Regeneron), R727CL1118 (Regeneron), 404173-CS2 (ISIS), EFC12626 (Sanofi-aventis), EFC12347 (Sanofi-aventis), M11-352 (Abbott), MK-3102-026 (Merck), TAK-875_304 (Takeda), TAK-875_306 (Takeda), INNOVATE (LMC), MK8835-002 (Merck), Carmelina(Boehringer Ingelheim), ISIS404173-CS2(ISIS), APD356-G000-401 (Eisai), B1481022 (Pfizer), B1481038 (Pfizer), CREDENCE (Janssen Research), B1481045 (Pfizer), STRENGTH (AstraZeneca), DERIVE (AstraZeneca), etc.
1999-2011	Sub-investigator for The VA Cooperative Trial (a seven year prospective randomized study looking at the macrovascular complications in relation to glycemic control in Type 2 Diabetes) "A case of Gamma Hydroxybutyrate (GHB) induced delirium". Muhlenberg Hospital, 1999 "A Multicenter, Open-Label, Utilization Study of Cardizem* CD for the Treatment of Mild to Moderate Hypertension in current Medical Practice". Scarborough Grace Hospital